Bruce Sands, MD: Results from the VEGA Study for Ulcerative Colitis


There is a need to study more combination therapies for the treatment of inflammatory bowel disease.

Many investigators fear the limits of monotherapies for treating inflammatory bowel disease (IBD) may soon be reached.

However, new results from the VEGA study shows a combination therapy of guselkumab and golimumab could be an effective answer for treating patients with ulcerative colitis.

In the phase 2a proof-of-concept trial, investigators found 83.1% of patients in the treatment group achieved a clinical response and 36.6% of patients treated with the combination therapy achieved clinical remission.

The high rates of clinical response and remission are both higher than the response and remission rates of patients treated with guselkumab alone (74.6%; 21.1%) and golimumab alone (61.1%; 22.2%).

There was also a greater proportion of patients who achieved endoscopic improvement and endoscopic normalization.

Guselkumab is an interleukin (IL)-23p19 subunit antagonist, while golimumab is a tumor necrosis factor-alpha (TNFα) antagonist.

In an interview with HCPLive®, Bruce E. Sands, MD, MS, Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai, and the Mount Sinai Hospital, and lead study author, explained why a study like VEGA is needed at this time.

The safety results of the trial was also favorable, with adverse events comparable among different treatment groups.

Related Videos
Taha Qazi, MD | Credit: Cleveland Clinic
Taha Qazi, MD | Cleveland Clinic
Vipul Jairath, MBChB, DPhil | Credit: LinkedIn
Marla Dubinsky, MD | Credit: LinkedIn
Adam Faye, MD: Treating the Older Population With IBD
Jordan Axelrad, MD: Assessing the Risk of Cancer for IBD Patients
Jan Wehkamp, MD: Promising New Guselkumab Data From DDW 2023
Taha Qazi, MD: Improving the Quality of Life for Patients Following Pouch Surgery
Jessica Allegretti, MD, MPH: An Update on the Quasar Study at DDW 2023
© 2024 MJH Life Sciences

All rights reserved.